{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:34:17Z","timestamp":1789097657429,"version":"build-2803163510"},"reference-count":55,"publisher":"Endocrinology Research Centre","issue":"1","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>The widespread introduction of genetic testing in recent years has made it possible to determine that more than a third of cases of pheochromocytomas and paragangliomas (PPPGs) are caused by germline mutations. Despite the variety of catecholamine-producing tumors manifestations, there is a sufficient number of clinical and laboratory landmarks that suggest a hereditary genesis of the disease and even a specific syndrome. These include a family history, age of patient, presence of concomitant conditions, and symptoms of the disease. Considering that each of the mutations is associated with certain diseases that often determine tactics of treatment and examination of a patient, e.g. high risk of various malignancies. Awareness of the practitioner on the peculiarities of the course of family forms of PPPGs will allow improving the tactics of managing these patients.<\/jats:p><jats:p>The article provides up-to-date information on the prevalence of hereditary PPPGs. The modern views on the pathogenesis of the disease induced by different mutations are presented. The main hereditary syndromes associated with PPPGs are described, including multiple endocrine neoplasia syndrome type 2A and 2B, type 1 neurofibromatosis, von Hippel-Lindau syndrome, hereditary paraganglioma syndrome, as well as clinical and laboratory features of the tumor in these conditions. The main positions on the necessity of genetic screening in patients with PPPGs are given.<\/jats:p>","DOI":"10.14341\/probl12834","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T16:05:35Z","timestamp":1646755535000},"page":"8-17","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":13,"title":["Clinical and laboratory features of hereditary pheochromocytoma and paraganglioma"],"prefix":"10.14341","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-4174","authenticated-orcid":true,"given":"D. V.","family":"Rebrova","sequence":"first","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-105X","authenticated-orcid":true,"given":"N. V.","family":"Vorokhobina","sequence":"additional","affiliation":[{"name":"North-Western State Medical University n.a. I.I. Mechnikov"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-7891","authenticated-orcid":true,"given":"E. N.","family":"Imyanitov","sequence":"additional","affiliation":[{"name":"National Medical Research Center of Oncology n.a. N.N. Petrov"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-778X","authenticated-orcid":true,"given":"V F.","family":"Rusakov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-0251","authenticated-orcid":true,"given":"L. M.","family":"Krasnov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-5081","authenticated-orcid":true,"given":"I. V.","family":"Sleptsov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-664X","authenticated-orcid":true,"given":"R. A.","family":"Chernikov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-811X","authenticated-orcid":true,"given":"E. A.","family":"Fedorov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-0025","authenticated-orcid":true,"given":"A. A.","family":"Semenov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6986-1034","authenticated-orcid":true,"given":"I. K.","family":"Chinchuk","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7912-4580","authenticated-orcid":true,"given":"I. V.","family":"Sablin","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-5204","authenticated-orcid":true,"given":"M. A.","family":"Alekseev","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-2527","authenticated-orcid":true,"given":"O. V.","family":"Kuleshov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3554-1387","authenticated-orcid":true,"given":"Ju. N","family":"Fedotov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5458","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Mel'nichenko G.A., Troshina E.A., Bel'tsevich D.G., et al. Russian Association of Endocrinologists clinical practice guidelines for diagnosis and treatment of pheochromocytoma and paraganglioma. Endocrine Surgery. 2015;9(3):15-33. (In Russ.) https:\/\/doi.org\/10.14341\/serg2015315-33","DOI":"10.14341\/serg2015315-33"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ilias I, Thomopoulos C. Addressing delays in the diagnosis of pheochromocytoma\/paraganglioma. Expert Rev Endocrinol Metab. 2019;14(5):359-363. https:\/\/doi.org\/10.1080\/17446651.2019.1657007","DOI":"10.1080\/17446651.2019.1657007"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Stolk RF, Bakx C, Mulder J, Timmers HJLM, et al. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? J Clin Endocrinol Metab. 2013;98(3):1100-1106. https:\/\/doi.org\/10.1210\/jc.2012-3669","DOI":"10.1210\/jc.2012-3669"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Geroula A, Deutschbein T, Langton K, et al. Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur J Endocrinol. 2019;181(4):409-420. https:\/\/doi.org\/10.1530\/EJE-19-0159","DOI":"10.1530\/EJE-19-0159"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Klingler PJ, Fox TP, Menke DM, et al. Pheochromocytoma in an incidentally discovered asymptomatic cystic adrenal mass. Mayo Clin Proc. 2000;75(5):517-520. https:\/\/doi.org\/10.4065\/75.5.517","DOI":"10.1016\/S0025-6196(11)64222-5"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. https:\/\/doi.org\/10.1210\/jc.2014-1498","DOI":"10.1210\/jc.2014-1498"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Rebrova DV, Rusakov VF, Fedorov EA et al. Rare case of pheochromocytoma with calcitonin hypersecretion. Pharmateca. 2021;28(4):90-98. (In Russ.) https:\/\/doi.org\/10.18565\/pharmateca.2021.4.90-98","DOI":"10.18565\/pharmateca.2021.4.90-98"},{"key":"ref8","unstructured":"Shafigullina ZR, Petrova MM, Shustov SB, et al. A case of combination ACTH-ectopic Cushing's syndrome and pheochromocytoma. Russian Family Doctor. 2013;17(4):43-46. (In Russ.)"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Patel D, Phay JE, Yen TWF, et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine\/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Ann Surg Oncol. 2020;27(5):1329-1337. https:\/\/doi.org\/10.1245\/s10434-020-08220-3","DOI":"10.1245\/s10434-020-08220-3"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 2020;54(2):159-168. https:\/\/doi.org\/10.14744\/SEMB.2020.18794","DOI":"10.14744\/SEMB.2020.18794"},{"key":"ref11","unstructured":"Van Der Horst-Schrivers ANA, Osinga TE, Kema IP, et al. Dopamine excess in patients with head and neck paragangliomas. Anticancer Res. 2010;30(12):5153-5158."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Yasunari K, Kohno M, Minami M, et al. A dopamine-secreting pheochromocytoma. J Cardiovasc Pharmacol. 2000;36 Suppl 2:S75-77. https:\/\/doi.org\/10.1097\/00005344-200000006-00016","DOI":"10.1097\/00005344-200000006-00016"},{"key":"ref13","unstructured":"Else T, Greenberg S, Fishbein L. Hereditary Paraganglioma-Pheochromocytoma Syndromes. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews\u00ae. University of Washington, Seattle; 1993. Accessed June 19, 2021. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1548"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Katabathina VS, Rajebi H, Chen M, et al. Genetics and imaging of pheochromocytomas and paragangliomas: current update. Abdom Radiol (NY). 2020;45(4):928-944. https:\/\/doi.org\/10.1007\/s00261-019-02044-w","DOI":"10.1007\/s00261-019-02044-w"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Fishbein L. Pheochromocytoma\/Paraganglioma: Is This a Genetic Disorder? Curr Cardiol Rep. 2019;21(9):104. https:\/\/doi.org\/10.1007\/s11886-019-1184-y","DOI":"10.1007\/s11886-019-1184-y"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14(2):108-119. https:\/\/doi.org\/10.1038\/nrc3648","DOI":"10.1038\/nrc3648"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Granberg D, Juhlin CC, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. J Clin Endocrinol Metab. 2021;106(5):e1937-e1952. https:\/\/doi.org\/10.1210\/clinem\/dgaa982","DOI":"10.1210\/clinem\/dgaa982"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Antonio K, Valdez MMN, Mercado-Asis L, Ta\u00efeb D, Pacak K. Pheochromocytoma\/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg. 2020;9(1):105-123. https:\/\/doi.org\/10.21037\/gs.2019.10.25","DOI":"10.21037\/gs.2019.10.25"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"N\u00f6lting S, Ullrich M, Pietzsch J, et al. Current Management of Pheochromocytoma\/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers (Basel). 2019;11(10):E1505. https:\/\/doi.org\/10.3390\/cancers11101505","DOI":"10.3390\/cancers11101505"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Fishbein L, Leshchiner I, Walter V, et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017;31(2):181-193. https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001","DOI":"10.1016\/j.ccell.2017.01.001"},{"key":"ref21","unstructured":"Lloyd R, Osamura R, Kloppel G, Rosai J, eds. WHO Classification of Tumors of Endocrine Organs edited by Lloyd RV, Osamura RY, Kloppel G, Rosai J. - 4th Edition. 4th ed. IARC; 2017."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Buffet A, Burnichon N, Favier J, Gimenez-Roqueplo A-P. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101416. https:\/\/doi.org\/10.1016\/j.beem.2020.101416","DOI":"10.1016\/j.beem.2020.101416"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"McDonnell JE, Gild ML, Clifton-Bligh RJ, Robinson BG. Multiple endocrine neoplasia: an update. Intern Med J. 2019;49(8):954-961. https:\/\/doi.org\/10.1111\/imj.14394","DOI":"10.1111\/imj.14394"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Chen H, Sippel RS, O\u2019Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775-783. https:\/\/doi.org\/10.1097\/MPA.0b013e3181ebb4f0","DOI":"10.1097\/MPA.0b013e3181ebb4f0"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Makri A, Akshintala S, Derse-Anthony C, et al. Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B. J Clin Endocrinol Metab. 2019;104(1):7-12. https:\/\/doi.org\/10.1210\/jc.2018-00705","DOI":"10.1210\/jc.2018-00705"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Galan SR, Kann PH. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clin Endocrinol (Oxf). 2013;78(2):165-175. https:\/\/doi.org\/10.1111\/cen.12071","DOI":"10.1111\/cen.12071"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Wohllk N, Schweizer H, Erlic Z, et al. Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol Metab. 2010;24(3):371-387. https:\/\/doi.org\/10.1016\/j.beem.2010.02.001","DOI":"10.1016\/j.beem.2010.02.001"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. https:\/\/doi.org\/10.1089\/thy.2014.0335","DOI":"10.1089\/thy.2014.0335"},{"key":"ref29","unstructured":"Yasir M, Mulji NJ, Kasi A. Multiple Endocrine Neoplasias Type 2. In: StatPearls. StatPearls Publishing; 2021. Accessed June 20, 2021. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519054"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75-86. https:\/\/doi.org\/10.1016\/B978-0-444-62702-5.00004-4","DOI":"10.1016\/B978-0-444-62702-5.00004-4"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123(1):124-133. https:\/\/doi.org\/10.1542\/peds.2007-3204","DOI":"10.1542\/peds.2007-3204"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Zinnamosca L, Petramala L, Cotesta D, et al. Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Arch Dermatol Res. 2011;303(5):317-325. https:\/\/doi.org\/10.1007\/s00403-010-1090-z","DOI":"10.1007\/s00403-010-1090-z"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"K\u00e9p\u00e9n\u00e9kian L, Mognetti T, Lifante J-C, et al. Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1. Eur J Endocrinol. 2016;175(4):335-344. https:\/\/doi.org\/10.1530\/EJE-16-0233","DOI":"10.1530\/EJE-16-0233"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Zografos GN, Vasiliadis GK, Zagouri F, et al. Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. World J Surg Oncol. 2010;8:14. https:\/\/doi.org\/10.1186\/1477-7819-8-14","DOI":"10.1186\/1477-7819-8-14"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Jafri M, Maher ER. The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol. 2012;166(2):151-158. https:\/\/doi.org\/10.1530\/EJE-11-0497","DOI":"10.1530\/EJE-11-0497"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Shinall MC, Sol\u00f3rzano CC. Pheochromocytoma in Neurofibromatosis Type 1: When Should it Be Suspected? Endocr Pract. 2014;20(8):792-796. https:\/\/doi.org\/10.4158\/EP13417.OR","DOI":"10.4158\/EP13417.OR"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Aronow ME, Wiley HE, Gaudric A, et al. VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects. Retina. 2019;39(12):2243-2253. https:\/\/doi.org\/10.1097\/IAE.0000000000002555","DOI":"10.1097\/IAE.0000000000002555"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617-623. https:\/\/doi.org\/10.1038\/ejhg.2010.175","DOI":"10.1038\/ejhg.2010.175"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Opocher G, Schiavi F. Genetics of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab. 2010;24(6):943-956. https:\/\/doi.org\/10.1016\/j.beem.2010.05.001","DOI":"10.1016\/j.beem.2010.05.001"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552-565. https:\/\/doi.org\/10.1056\/NEJMra1806651","DOI":"10.1056\/NEJMra1806651"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Neumann HPH, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292(8):943-951. https:\/\/doi.org\/10.1001\/jama.292.8.943","DOI":"10.1001\/jama.292.8.943"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Schiavi F, Dematt\u00e8 S, Cecchini ME, et al. The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression. J Clin Endocrinol Metab. 2012;97(4):E637-641. https:\/\/doi.org\/10.1210\/jc.2011-2597","DOI":"10.1210\/jc.2011-2597"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med. 2009;266(1):19-42. https:\/\/doi.org\/10.1111\/j.1365-2796.2009.02111.x","DOI":"10.1111\/j.1365-2796.2009.02111.x"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Hensen EF, Bayley J-P. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Fam Cancer. 2011;10(2):355-363. https:\/\/doi.org\/10.1007\/s10689-010-9402-1","DOI":"10.1007\/s10689-010-9402-1"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab. 2009;94(8):2817-2827. https:\/\/doi.org\/10.1210\/jc.2008-2504","DOI":"10.1210\/jc.2008-2504"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505-4509. https:\/\/doi.org\/10.1210\/jc.2006-0423","DOI":"10.1210\/jc.2006-0423"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96(9):E1472-1476. https:\/\/doi.org\/10.1210\/jc.2011-1043","DOI":"10.1210\/jc.2011-1043"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Muth A, Crona J, Gimm O, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med. 2019;285(2):187-204. https:\/\/doi.org\/10.1111\/joim.12869","DOI":"10.1111\/joim.12869"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Yao L, Schiavi F, Cascon A, et al. Spectrum and prevalence of FP\/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010;304(23):2611-2619. https:\/\/doi.org\/10.1001\/jama.2010.1830","DOI":"10.1001\/jama.2010.1830"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42(3):229-233. https:\/\/doi.org\/10.1038\/ng.533","DOI":"10.1038\/ng.533"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Comino-M\u00e9ndez I, Gracia-Azn\u00e1rez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43(7):663-667. https:\/\/doi.org\/10.1038\/ng.861","DOI":"10.1038\/ng.861"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Turchini J, Cheung VKY, Tischler AS, et al. Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology. 2018;72(1):97-105. https:\/\/doi.org\/10.1111\/his.13402","DOI":"10.1111\/his.13402"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Zhang C, Li L, Zhang Y, Zeng C. Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment. Front Oncol. 2021;11:686556. https:\/\/doi.org\/10.3389\/fonc.2021.686556","DOI":"10.3389\/fonc.2021.686556"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Brito JP, Asi N, Bancos I, et al. Testing for germline mutations in sporadic pheochromocytoma\/paraganglioma: a systematic review. Clin Endocrinol (Oxf). 2015;82(3):338-345. https:\/\/doi.org\/10.1111\/cen.12530","DOI":"10.1111\/cen.12530"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab. 2006;91(8):2851-2858. https:\/\/doi.org\/10.1210\/jc.2005-2178","DOI":"10.1210\/jc.2005-2178"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/12834\/10218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T16:21:35Z","timestamp":1646756495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/12834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,6]]}},"URL":"https:\/\/doi.org\/10.14341\/probl12834","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}